Terapias Basadas en Citoquinas
Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas
Madrid, EspañaPublicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (15)
2023
-
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005
2022
-
Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 55-96
-
Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment
Life, Vol. 12, Núm. 11
-
Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria
Science Translational Medicine, Vol. 14, Núm. 627
2021
-
High prevalence of insulin resistance in asymptomatic patients with acute intermittent porphyria and liver-targeted insulin as a novel therapeutic approach
Biomedicines, Vol. 9, Núm. 3, pp. 1-18
2020
2019
-
Messenger RNA therapy for rare genetic metabolic diseases
Gut, Vol. 68, Núm. 7, pp. 1323-1330
2018
-
Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria
Human Molecular Genetics, Vol. 27, Núm. 21, pp. 3688-3696
-
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria
Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909
2017
-
Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice
Cell Death and Disease, Vol. 8, Núm. 10
2013
-
Targeting Interferon-α to the Liver: Apolipoprotein A-I as a Scaffold for Protein Delivery
Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges (John Wiley and Sons), pp. 441-452
2012
-
A Semliki Forest virus vector engineered to express IFNα induces efficient elimination of established tumors
Gene Therapy, Vol. 19, Núm. 3, pp. 271-278
-
Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin
International Journal of Cancer, Vol. 131, Núm. 3, pp. 641-651
2009
-
Advances in interleukin-12 gene therapy for acquired liver diseases
Current Gene Therapy, Vol. 9, Núm. 2, pp. 62-71
2007
-
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer
Journal of Hepatology, Vol. 47, Núm. 6, pp. 807-815